Citius Oncology recently presented data showing significant quality of life improvements in CTCL patients treated with LYMPHIR at an international conference in Berlin.

This systematic review and meta-analysis evaluates the efficacy and safety of targeted and immune-based monotherapies for cutaneous T-cell lymphomas and characterizes subtype-specific outcomes in myco...

Richardson claims her mom started having health problems shortly after her first injection. She was then diagnosed with T-cell lymphoma, or CTCL, in September, which at first she was told was treat…

Extracorporeal photopheresis (ECP) is an immunosuppressive therapy with long-established indications for treating T cell-mediated diseases, including steroid-refractory, acute or chronic graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL) and chronic rejection after heart or lung transplantation1,2. The ECP procedure involves collecting autologous peripheral blood leucocytes by leukapheresis, which are separated from erythrocytes and platelets, then returned to patients. Passage of leucocytes through the extracorporeal circuit induces cellular activation, release of soluble mediators and metabolic products, modification of plasma proteins and fragmentation of physically damaged cells3,4. The resulting leucocyte concentrates are then incubated with a DNA-intercalating agent, 8-methoxypsoralen (8-MOP), before exposure to ultraviolet A (UVA) irradiation. In the THERAKOS™ CELLEX™ Photopheresis System, these steps are performed within the integrated, online system as part of a single clinical procedure, whereas in offline ECP systems, the collected leucocytes are transferred to separate devices for UVA irradiation5. Excitation of 8-MOP bound to DNA with UVA causes double-stranded breaks, which initiate apoptosis6. Thus, ECP results in a heterogeneous cell suspension in autologous plasma, which consists of mixed leucocyte types at various stages of apoptotic and non-apoptotic cell death. There is an emerging consensus that ECP acts primarily through mononuclear phagocytes that are driven to a tolerogenic...

Extracorporeal photopheresis (ECP) is an immunosuppressive therapy with long-established indications for treating T cell-mediated diseases, including steroid-refractory, acute or chronic graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL) and chronic rejection after heart or lung transplantation1,2. The ECP procedure involves collecting autologous peripheral blood leucocytes by leukapheresis, which are separated from erythrocytes and platelets, then returned to patients. Passage of leucocytes through the extracorporeal circuit induces cellular activation, release of soluble mediators and metabolic products, modification of plasma proteins and fragmentation of physically damaged cells3,4. The resulting leucocyte concentrates are then incubated with a DNA-intercalating agent, 8-methoxypsoralen (8-MOP), before exposure to ultraviolet A (UVA) irradiation. In the THERAKOS™ CELLEX™ Photopheresis System, these steps are performed within the integrated, online system as part of a single clinical procedure, whereas in offline ECP systems, the collected leucocytes are transferred to separate devices for UVA irradiation5. Excitation of 8-MOP bound to DNA with UVA causes double-stranded breaks, which initiate apoptosis6. Thus, ECP results in a heterogeneous cell suspension in autologous plasma, which consists of mixed leucocyte types at various stages of apoptotic and non-apoptotic cell death. There is an emerging consensus that ECP acts primarily through mononuclear phagocytes that are driven to a tolerogenic...

Citius Oncology has announced impressive growth in LYMPHIR® shipments, showcasing 120% growth to U.S. wholesalers during Q4 2026. Institutional demand remains strong.

The Cutaneous T-Cell Lymphoma (CTCL) market was valued at USD 1.2 billion in 2025 and is poised to grow from USD 1.

The Cutaneous T-Cell Lymphoma (CTCL) market was valued at USD 1.2 billion in 2025 and is poised to grow from USD 1.

Sobi and Innate Pharma have officially established a partnership to advance the development of lacutamab for treating Sézary syndrome, a subtype of cutaneous T-cell lymphoma.

Innate Pharma (IPHA) reported first-half 2026 results and a new global partnership with Sobi for lacutamab, including a USD 75 million upfront payment following transaction closing on September 16, 2026.The Sobi deal supports initiation of the TELLOMAK-3 Phase 3 CTCL study, with first patient expected in Q1 2027, and could bring up to USD 505 million in additional milestones plus tiered double-digit royalties. Innate also completed a €30 million private placement of 17,647,059 new shares and expects, together with the Sobi upfront payment, to extend its cash runway to the end of Q1 2028. As of June 30, 2026, cash, cash equivalents, short-term investments and financial assets were €21.4 million and financial liabilities were €20.2 million. Revenue and other income reached €5.7 million, while operating expenses fell to €24.7 million, driven by lower R&D and G&A costs.

In a single-centre retrospective cohort of 605 patients with cutaneous T-cell lymphoma (CTCL), a prior history of atopic dermatitis (AD) was independently

YouTube video by Mike Watson

Published in Frontiers in immunology

SE-producing S. aureus promotes skin barrier impairment in CTCL through cytokine-driven, JAK-dependent repression of structural proteins in keratinocytes. These findings identify microbial-immune crosstalk...